4. September 2008 08:08
Invitrogen Corporation today announced that it has signed non-exclusive agreements with New England Biolabs, Inc., QIAGEN GmbH, and Kirkegaard & Perry Laboratories, Inc. (KPL), whereby the companies have licensed Invitrogen's patented technology covering the random prime amplification of nucleic acids. Financial terms of the agreements were not disclosed.
The Invitrogen technology covered in these agreements involves methods and kits for substantially amplifying nucleic acids. It is useful in several common laboratory techniques, including random primed labeling reactions, first-strand cDNA synthesis, and whole genome amplification.
"Our random prime amplification technology is an important tool in our premier portfolio of products for genetic analysis," said Amy Butler, Invitrogen Vice President of Gene Expression Profiling. "By making this technology broadly available to other companies through licensing, we can extend the benefit to a greater number of researchers and advance this rapidly growing field of research."
http://www.invitrogen.com
News-Medical.Net provides this medical information service in accordance
with these
terms and conditions.
Please note that medical information found
on this website is designed to support, not to replace the relationship
between patient and physician/doctor and the medical advice they may provide.
Subscribe